O	0	10	Menopausal
O	11	19	Estrogen
O	19	20	-
O	20	25	Alone
O	26	33	Therapy
O	34	37	and
O	38	44	Health
O	45	53	Outcomes
O	54	56	in
O	57	62	Women
O	63	67	With
O	68	71	and
O	72	79	Without
O	80	89	Bilateral
O	90	102	Oophorectomy
O	102	103	:
O	104	105	A
O	106	116	Randomized
O	117	122	Trial
O	122	123	.

O	124	131	Whether
O	132	138	health
O	139	147	outcomes
O	148	150	of
O	151	161	menopausal
O	162	170	estrogen
O	171	178	therapy
O	179	185	differ
O	186	193	between
O	194	199	women
O	200	204	with
O	205	208	and
O	209	216	without
O	217	226	bilateral
O	227	235	salpingo
O	235	236	-
O	236	248	oophorectomy
O	249	250	(
O	250	253	BSO
O	253	254	)
O	255	257	is
O	258	265	unknown
O	265	266	.

O	267	269	To
O	270	277	examine
O	278	286	estrogen
O	287	294	therapy
O	295	303	outcomes
O	304	306	by
O	307	310	BSO
O	311	317	status
O	317	318	,
O	319	323	with
O	324	334	additional
O	335	349	stratification
O	350	352	by
O	353	355	10
O	355	356	-
O	356	360	year
O	361	364	age
O	365	371	groups
O	371	372	.

O	373	381	Subgroup
O	382	390	analyses
O	391	393	of
O	394	397	the
O	398	408	randomized
O	409	414	Women
O	414	415	'
O	415	416	s
O	417	423	Health
O	424	434	Initiative
O	435	443	Estrogen
O	443	444	-
O	444	449	Alone
O	450	455	Trial
O	455	456	.

O	457	458	(
O	458	472	ClinicalTrials
O	472	473	.
O	473	476	gov
O	476	477	:
O	478	489	NCT00000611
O	489	490	)
O	490	491	.

O	492	494	40
B-location	495	496	U
I-location	496	497	.
I-location	497	498	S
I-location	498	499	.
O	500	508	clinical
O	509	516	centers
O	516	517	.

B-total-participants	518	522	9939
O	523	528	women
O	529	533	aged
B-age	534	536	50
I-age	537	539	to
I-age	540	542	79
I-age	543	548	years
B-eligibility	549	553	with
I-eligibility	554	559	prior
I-eligibility	560	572	hysterectomy
I-eligibility	573	576	and
I-eligibility	577	582	known
I-eligibility	583	595	oophorectomy
I-eligibility	596	602	status
O	602	603	.

B-intervention	604	614	Conjugated
I-intervention	615	621	equine
I-intervention	622	631	estrogens
I-intervention	632	633	(
I-intervention	633	636	CEE
I-intervention	636	637	)
O	638	639	(
O	639	640	0
O	640	641	.
O	641	644	625
O	645	647	mg
O	647	648	/
O	648	649	d
O	649	650	)
O	651	653	or
B-control	654	661	placebo
O	662	665	for
O	666	667	a
O	668	674	median
O	675	677	of
O	678	679	7
O	679	680	.
O	680	681	2
O	682	687	years
O	687	688	.

B-outcome-Measure	689	698	Incidence
I-outcome-Measure	699	701	of
I-outcome-Measure	702	710	coronary
I-outcome-Measure	711	716	heart
I-outcome-Measure	717	724	disease
O	725	728	and
B-outcome-Measure	729	737	invasive
I-outcome-Measure	738	744	breast
I-outcome-Measure	745	751	cancer
O	752	753	(
O	753	756	the
O	757	762	trial
O	762	763	'
O	763	764	s
O	765	766	2
O	767	774	primary
O	775	778	end
O	779	785	points
O	785	786	)
O	786	787	,
B-outcome-Measure	788	791	all
I-outcome-Measure	791	792	-
I-outcome-Measure	792	797	cause
I-outcome-Measure	798	807	mortality
O	807	808	,
O	809	812	and
O	813	814	a
B-outcome-Measure	815	816	"
I-outcome-Measure	816	822	global
I-outcome-Measure	823	828	index
I-outcome-Measure	828	829	"
O	830	831	(
O	831	836	these
O	837	840	end
O	841	847	points
O	848	852	plus
O	853	859	stroke
O	859	860	,
O	861	870	pulmonary
O	871	879	embolism
O	879	880	,
O	881	891	colorectal
O	892	898	cancer
O	898	899	,
O	900	903	and
O	904	907	hip
O	908	916	fracture
O	916	917	)
O	918	924	during
O	925	928	the
O	929	941	intervention
O	942	947	phase
O	948	951	and
O	952	954	18
O	954	955	-
O	955	959	year
O	960	970	cumulative
O	971	977	follow
O	977	978	-
O	978	980	up
O	980	981	.

O	982	985	The
O	986	993	effects
O	994	996	of
O	997	1000	CEE
O	1001	1006	alone
O	1007	1010	did
O	1011	1014	not
O	1015	1021	differ
O	1022	1035	significantly
O	1036	1045	according
O	1046	1048	to
O	1049	1052	BSO
O	1053	1059	status
O	1059	1060	.

O	1061	1068	However
O	1068	1069	,
O	1070	1073	age
O	1074	1082	modified
O	1083	1086	the
O	1087	1093	effect
O	1094	1096	of
O	1097	1100	CEE
O	1101	1103	in
O	1104	1109	women
O	1110	1114	with
O	1115	1120	prior
O	1121	1124	BSO
O	1124	1125	.

O	1126	1132	During
O	1133	1136	the
O	1137	1149	intervention
O	1150	1155	phase
O	1155	1156	,
O	1157	1160	CEE
O	1161	1164	was
O	1165	1178	significantly
O	1179	1189	associated
O	1190	1194	with
O	1195	1196	a
B-outcome	1197	1200	net
I-outcome	1201	1208	adverse
I-outcome	1209	1215	effect
O	1216	1217	(
O	1217	1223	hazard
O	1224	1229	ratio
O	1230	1233	for
O	1234	1240	global
O	1241	1246	index
O	1246	1247	,
O	1248	1249	1
O	1249	1250	.
O	1250	1252	42
O	1253	1254	[
O	1254	1256	95
O	1256	1257	%
O	1258	1260	CI
O	1260	1261	,
O	1262	1263	1
O	1263	1264	.
O	1264	1266	09
O	1267	1269	to
O	1270	1271	1
O	1271	1272	.
O	1272	1274	86
O	1274	1275	]
O	1275	1276	)
O	1277	1279	in
O	1280	1285	older
O	1286	1291	women
O	1292	1293	(
O	1293	1297	aged
O	1298	1299	â
O	1299	1300	‰
O	1300	1301	¥
O	1301	1303	70
O	1304	1309	years
O	1309	1310	)
O	1310	1311	,
O	1312	1315	but
O	1316	1319	the
O	1320	1326	global
O	1327	1332	index
O	1333	1336	was
O	1337	1340	not
O	1341	1349	elevated
O	1350	1352	in
O	1353	1360	younger
O	1361	1366	women
O	1367	1368	(
O	1368	1369	P
O	1370	1375	trend
O	1376	1378	by
O	1379	1382	age
O	1383	1384	=
O	1385	1386	0
O	1386	1387	.
O	1387	1390	016
O	1390	1391	)
O	1391	1392	.

O	1393	1399	During
O	1400	1410	cumulative
O	1411	1417	follow
O	1417	1418	-
O	1418	1420	up
O	1420	1421	,
O	1422	1427	women
O	1428	1432	aged
O	1433	1435	50
O	1436	1438	to
O	1439	1441	59
O	1442	1447	years
O	1448	1452	with
O	1453	1456	BSO
O	1457	1460	had
O	1461	1462	a
O	1463	1472	treatment
O	1472	1473	-
O	1473	1483	associated
B-outcome	1484	1493	reduction
I-outcome	1494	1496	in
I-outcome	1497	1500	all
I-outcome	1500	1501	-
I-outcome	1501	1506	cause
I-outcome	1507	1516	mortality
O	1517	1518	(
O	1518	1524	hazard
O	1525	1530	ratio
O	1530	1531	,
O	1532	1533	0
O	1533	1534	.
O	1534	1536	68
O	1537	1538	[
O	1538	1540	CI
O	1540	1541	,
O	1542	1543	0
O	1543	1544	.
O	1544	1546	48
O	1547	1549	to
O	1550	1551	0
O	1551	1552	.
O	1552	1554	96
O	1554	1555	]
O	1555	1556	)
O	1556	1557	,
O	1558	1565	whereas
O	1566	1571	older
O	1572	1577	women
O	1578	1582	with
O	1583	1586	BSO
O	1587	1590	had
O	1591	1593	no
O	1594	1603	reduction
O	1604	1605	(
O	1605	1606	P
O	1607	1612	trend
O	1613	1615	by
O	1616	1619	age
O	1620	1621	=
O	1622	1623	0
O	1623	1624	.
O	1624	1627	034
O	1627	1628	)
O	1628	1629	.

O	1630	1635	There
O	1636	1639	was
O	1640	1642	no
O	1643	1654	significant
O	1655	1666	association
O	1667	1674	between
O	1675	1678	CEE
O	1679	1682	and
O	1683	1691	outcomes
O	1692	1697	among
O	1698	1703	women
O	1704	1708	with
O	1709	1718	conserved
O	1719	1726	ovaries
O	1726	1727	,
O	1728	1738	regardless
O	1739	1741	of
O	1742	1745	age
O	1745	1746	.

O	1747	1750	The
O	1751	1757	timing
O	1758	1760	of
O	1761	1764	CEE
O	1765	1767	in
O	1768	1776	relation
O	1777	1779	to
O	1780	1783	BSO
O	1784	1790	varied
O	1790	1791	;
O	1792	1799	several
O	1800	1811	comparisons
O	1812	1816	were
O	1817	1821	made
O	1822	1829	without
O	1830	1840	adjustment
O	1841	1844	for
O	1845	1853	multiple
O	1854	1861	testing
O	1861	1862	.

O	1863	1866	The
O	1867	1874	effects
O	1875	1877	of
O	1878	1881	CEE
O	1882	1885	did
O	1886	1889	not
O	1890	1896	differ
O	1897	1899	by
O	1900	1903	BSO
O	1904	1910	status
O	1911	1913	in
O	1914	1917	the
O	1918	1925	overall
O	1926	1932	cohort
O	1932	1933	,
O	1934	1937	but
O	1938	1942	some
O	1943	1951	findings
O	1952	1958	varied
O	1959	1961	by
O	1962	1965	age
O	1965	1966	.

O	1967	1972	Among
O	1973	1978	women
O	1979	1983	with
O	1984	1989	prior
O	1990	1993	BSO
O	1993	1994	,
O	1995	1997	in
O	1998	2003	those
O	2004	2008	aged
O	2009	2011	70
O	2012	2017	years
O	2018	2020	or
O	2021	2026	older
O	2026	2027	,
O	2028	2031	CEE
O	2032	2035	led
O	2036	2038	to
B-outcome	2039	2046	adverse
I-outcome	2047	2054	effects
O	2055	2061	during
O	2062	2065	the
O	2066	2075	treatment
O	2076	2082	period
O	2082	2083	,
O	2084	2091	whereas
O	2092	2097	women
O	2098	2106	randomly
O	2107	2115	assigned
O	2116	2118	to
O	2119	2122	CEE
O	2123	2129	before
O	2130	2133	age
O	2134	2136	60
O	2137	2143	seemed
O	2144	2146	to
O	2147	2153	derive
O	2154	2163	mortality
O	2164	2171	benefit
O	2172	2176	over
O	2177	2180	the
O	2181	2185	long
O	2186	2190	term
O	2190	2191	.

O	2192	2195	The
O	2196	2199	WHI
O	2200	2207	program
O	2208	2210	is
O	2211	2217	funded
O	2218	2220	by
O	2221	2224	the
O	2225	2233	National
O	2234	2239	Heart
O	2239	2240	,
O	2241	2245	Lung
O	2245	2246	,
O	2247	2250	and
O	2251	2256	Blood
O	2257	2266	Institute
O	2266	2267	;
O	2268	2276	National
O	2277	2287	Institutes
O	2288	2290	of
O	2291	2297	Health
O	2297	2298	;
O	2299	2302	and
O	2303	2304	U
O	2304	2305	.
O	2305	2306	S
O	2306	2307	.

O	2308	2318	Department
O	2319	2321	of
O	2322	2328	Health
O	2329	2332	and
O	2333	2338	Human
O	2339	2347	Services
O	2347	2348	.

O	2349	2354	Wyeth
O	2355	2361	Ayerst
O	2362	2369	donated
O	2370	2373	the
O	2374	2379	study
O	2380	2385	drugs
O	2385	2386	.
